Your session is about to expire
← Back to Search
Single-arm: Semaglutide for HIV (SLIM LIVER Trial)
SLIM LIVER Trial Summary
This trial will assess if a diabetes drug (Ozempic®) can reduce body fat and protect against heart & diabetes in HIV+ people. MRI will measure body fat.
- Prediabetes
- HIV
- Obesity
- Fatty Liver
- Insulin Resistance
SLIM LIVER Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 104 Patients • NCT04189848SLIM LIVER Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there a substantial risk associated with the utilization of Single-arm: Semaglutide?
"Despite a lack of data regarding efficacy, evidence supporting the safety of Semaglutide in Phase 2 trials has led to Power assigning it an overall rating of 2."
How many sites are hosting this experiment?
"As of now, this scientific experiment is being conducted at 7 research centres spread across Houston, Baltimore and Birmingham as well as 4 other cities. To reduce the need for travel, participants should pick a location close to them."
Is the research team currently looking for new participants?
"The details hosted on clinicaltrials.gov indicate that the initial posting of this trial was October 1st 2021 and it has since been edited on December 7th 2022, thus ruling out any further recruitment. Nonetheless, 674 other trials are still actively enrolling patients at the moment."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger